|
🐜
|
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
23 auth.
R. Bartsch,
A. Berghoff,
J. Furtner,
M. Marhold,
E. Bergen,
S. Roider-Schur,
A. Starzer,
H. Forstner,
B. Rottenmanner,
K. Dieckmann,
...
Z. Bago-Horvath,
H. Haslacher,
G. Widhalm,
A. Ilhan-Mutlu,
C. Minichsdorfer,
T. Fuereder,
T. Szekeres,
L. Oehler,
B. Gruenberger,
C. Singer,
A. Weltermann,
R. Puhr,
M. Preusser
|
7 |
2022 |
7
🐜
|
|
🐜
|
Mean Platelet Volume May Represent a Predictive Parameter for Overall Vascular Mortality and Ischemic Heart Disease
7 auth.
G. Slavka,
T. Perkmann,
H. Haslacher,
S. Greisenegger,
C. Marsik,
O. Wagner,
...
G. Endler
|
7 |
2011 |
7
🐜
|
|
🐜
|
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
17 auth.
F. Eskandary,
H. Regele,
L. Baumann,
G. Bond,
N. Kozakowski,
M. Wahrmann,
L. Hidalgo,
H. Haslacher,
C. Kaltenecker,
Marie-Bernadette Aretin,
...
R. Oberbauer,
M. Posch,
A. Staudenherz,
A. Handisurya,
J. Reeve,
P. Halloran,
G. Böhmig
|
7 |
2017 |
7
🐜
|
|
🐜
|
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
18 auth.
D. Mrak,
S. Tobudic,
M. Koblischke,
Marianne Graninger,
H. Radner,
D. Sieghart,
P. Hofer,
T. Perkmann,
H. Haslacher,
R. Thalhammer,
...
S. Winkler,
S. Blüml,
K. Stiasny,
J. Aberle,
J. Smolen,
L. Heinz,
D. Aletaha,
M. Bonelli
|
7 |
2021 |
7
🐜
|
|
🐢
|
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
10 auth.
T. Perkmann,
N. Perkmann-Nagele,
T. Koller,
P. Mucher,
A. Radakovics,
R. Marculescu,
...
M. Wolzt,
O. Wagner,
C. Binder,
H. Haslacher
|
7 |
2021 |
7
🐢
|
|
🐬
|
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
M. Bonelli,
D. Mrak,
T. Perkmann,
H. Haslacher,
D. Aletaha
|
7 |
2021 |
7
🐬
|
|
🐢
|
Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
15 auth.
T. Perkmann,
N. Perkmann-Nagele,
M. Breyer,
R. Breyer-Kohansal,
O. Burghuber,
S. Hartl,
D. Aletaha,
D. Sieghart,
P. Quehenberger,
R. Marculescu,
...
P. Mucher,
R. Strassl,
O. Wagner,
C. Binder,
H. Haslacher
|
6 |
2020 |
6
🐢
|
|
🐜
|
Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity
10 auth.
F. Ratzinger,
H. Haslacher,
W. Poeppl,
G. Hoermann,
J. Kovarik,
Sabrina Jutz,
...
P. Steinberger,
H. Burgmann,
Winfried F. Pickl,
K. Schmetterer
|
6 |
2014 |
6
🐜
|
|
🦁
|
Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank
8 auth.
H. Haslacher,
M. Gerner,
P. Hofer,
Andreas Jurkowitsch,
J. Hainfellner,
R. Kain,
...
O. Wagner,
T. Perkmann
|
6 |
2018 |
6
🦁
|
|
🐜
|
Arterial stiffness in acute COVID‐19 and potential associations with clinical outcome
15 auth.
S. Schnaubelt,
Julia Oppenauer,
Daniel Tihanyi,
Markus Mueller,
Eduardo Maldonado-Gonzalez,
Sara Zejnilovic,
H. Haslacher,
T. Perkmann,
R. Strassl,
Sonja Anders,
...
T. Stefenelli,
S. Zehetmayer,
R. Koppensteiner,
H. Domanovits,
O. Schlager
|
6 |
2021 |
6
🐜
|
